AI Verdict
RPRX has stronger fundamentals based on our AI analysis.
RPRX vs RDAR Fundamental Comparison
| Metric | RPRX | RDAR |
|---|---|---|
| Revenue | $2.4B | $0.0 |
| Net Income | $770.9M | $-739,514.0 |
| Net Margin | 32.4% | N/A |
| ROE | 7.9% | N/A |
| ROA | 3.9% | -62,617.6% |
| Current Ratio | 2.40x | 0.00x |
| Debt/Equity | 0.92x | N/A |
| EPS | $1.78 | $0.00 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RPRX vs RDAR: Frequently Asked Questions
Is RPRX or RDAR a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RPRX has stronger fundamentals. RPRX is rated HOLD (75% confidence) while RDAR is rated STRONG SELL (98% confidence). This is not investment advice.
How does RPRX compare to RDAR fundamentally?
Royalty Pharma plc has ROE of 7.9% vs Telvantis, Inc.'s N/A. Net margins are 32.4% vs N/A respectively.
Which stock pays higher dividends, RPRX or RDAR?
RPRX has a dividend yield of N/A or no dividend while RDAR has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RPRX or RDAR for long term?
For long-term investing, consider that RPRX has HOLD rating with 75% confidence, while RDAR has STRONG SELL rating with 98% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RPRX vs RDAR?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RPRX vs RDAR, the AI consensus favors RPRX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.